Too many reasons for a reply here, but overall the common theme is lack of regulation giving pharma more power to play on their patent-derived monopolies.

As for Switzerland, it's a small country with an economic model that doesn't scale/generalize. Even in Switzerland there's constant discussion about health care (insurance) being too expensive - though the biggest driver is wages not drug prices.

I am not sure if you read other news but I am not aware of constant discussions when our insurance is comparingly cheaper than for example Austria but we earn 3 times as much.